Aprogen Biologics (003060) Fundamentals 2026 — Revenue Analysis | SniperIQ
Aprogen Biologics (003060) is a KR-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₩26.1B, trading at ₩1980.00 on the KSC. This SniperIQ fundamentals page covers Aprogen Biologics's valuation, profitability (net margin -168.2%), revenue (₩73.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Aprogen Biologics's market cap?
Aprogen Biologics (003060) has a market capitalization of approximately ₩26.1B, trading at ₩1980.00 on the KSC. Market cap moves with the live share price.
What is Aprogen Biologics's P/E ratio?
Aprogen Biologics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Aprogen Biologics?
Aprogen Biologics runs a net profit margin of -168.2%, a gross margin of -30.8%, and an operating margin of -157.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Aprogen Biologics generate?
Aprogen Biologics reported revenue of ₩73.2B for fiscal year 2025, with net income of -₩170.3B and earnings per share (EPS) of -12923.54. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Aprogen Biologics pay a dividend?
Aprogen Biologics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Aprogen Biologics financially healthy?
Aprogen Biologics carries a debt-to-equity ratio of 1.12x and a current ratio of 0.67x, with a market beta of -0.18. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Aprogen Biologics a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Aprogen Biologics (003060) the key facts are: market cap ₩26.1B, revenue ₩73.2B, 52-week range 1869-10389.805. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Aprogen Biologics's full fundamentals live
Get Aprogen Biologics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.